Koninklijke Philips N.v (PHG)

$30.22

+0.39

(+1.31%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $29.95
    $30.28
    $30.22
    downward going graph

    0.89%

    Downside

    Day's Volatility :1.09%

    Upside

    0.2%

    downward going graph
  • $17.75
    $30.71
    $30.22
    downward going graph

    41.26%

    Downside

    52 Weeks Volatility :42.2%

    Upside

    1.6%

    downward going graph

Returns

PeriodKoninklijke Philips N.vSector (Health Care)Index (Russel 2000)
3 Months
14.9%
5.1%
0.0%
6 Months
49.25%
4.9%
0.0%
1 Year
41.68%
16.6%
0.0%
3 Years
-35.27%
13.2%
-22.3%

Highlights

Market Capitalization
27.9B
Book Value
$12.72
Earnings Per Share (EPS)
-0.65
PEG Ratio
0.35
Wall Street Target Price
27.06
Profit Margin
-2.32%
Operating Margin TTM
6.23%
Return On Assets TTM
1.36%
Return On Equity TTM
-4.59%
Revenue TTM
18.1B
Revenue Per Share TTM
19.77
Quarterly Revenue Growth YOY
-0.2%
Gross Profit TTM
7.2B
EBITDA
1.4B
Diluted Eps TTM
-0.65
Quarterly Earnings Growth YOY
5.85
EPS Estimate Current Year
1.67
EPS Estimate Next Year
1.87
EPS Estimate Current Quarter
0.27
EPS Estimate Next Quarter
0.39

Analyst Recommendation

Hold
    37%Buy
    55%Hold
    7%Sell
Based on 27 Wall street analysts offering stock ratings for Koninklijke Philips N.v(by analysts ranked 0 to 5 stars)
Based on 27 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
4
4
Hold
15
12
13
Sell
2
13
12

Analyst Forecast

What analysts predicted

Downside of 10.46%

Current $30.22
Target $27.06

Company Financials

FY18Y/Y Change
Revenue
20.6B
↑ 1.92%
Net Income
1.2B
↓ 34.22%
Net Profit Margin
6.02%
↓ 3.3%
FY19Y/Y Change
Revenue
21.6B
↑ 7.51%
Net Income
1.3B
↑ 7.16%
Net Profit Margin
6.0%
↓ 0.02%
FY20Y/Y Change
Revenue
23.8B
↑ 0.27%
Net Income
1.4B
↑ 1.63%
Net Profit Margin
6.08%
↑ 0.08%
FY21Y/Y Change
Revenue
19.4B
↓ 12.18%
Net Income
691.8M
↓ 48.44%
Net Profit Margin
3.57%
↓ 2.51%
FY22Y/Y Change
Revenue
18.9B
↑ 3.91%
Net Income
-1.7B
↓ 364.38%
Net Profit Margin
-9.08%
↓ 12.65%
FY23Y/Y Change
Revenue
19.8B
↑ 1.92%
Net Income
-508.4M
↓ 71.2%
Net Profit Margin
-2.56%
↑ 6.52%
Q1 FY23Q/Q Change
Revenue
4.5B
↓ 23.15%
Net Income
-709.6M
↑ 486.73%
Net Profit Margin
-15.91%
↓ 13.83%
Q2 FY23Q/Q Change
Revenue
4.8B
↑ 7.27%
Net Income
78.1M
↓ 110.86%
Net Profit Margin
1.61%
↑ 17.52%
Q3 FY23Q/Q Change
Revenue
4.8B
↑ 0.02%
Net Income
93.9M
↑ 22.22%
Net Profit Margin
1.97%
↑ 0.36%
Q4 FY23Q/Q Change
Revenue
5.5B
↑ 13.22%
Net Income
42.5M
↓ 55.68%
Net Profit Margin
0.77%
↓ 1.2%
Q1 FY24Q/Q Change
Revenue
4.5B
↓ 18.25%
Net Income
-1.1B
↓ 2661.54%
Net Profit Margin
-24.14%
↓ 24.91%
Q2 FY24Q/Q Change
Revenue
4.8B
↑ 7.83%
Net Income
485.3M
↓ 145.15%
Net Profit Margin
10.11%
↑ 34.25%
FY18Y/Y Change
Total Assets
29.6B
↑ 2.78%
Total Liabilities
15.8B
↑ 4.59%
FY19Y/Y Change
Total Assets
30.0B
↑ 3.7%
Total Liabilities
16.0B
↑ 3.28%
FY20Y/Y Change
Total Assets
33.7B
↑ 2.71%
Total Liabilities
19.2B
↑ 10.13%
FY21Y/Y Change
Total Assets
35.0B
↑ 11.72%
Total Liabilities
18.6B
↑ 4.27%
FY22Y/Y Change
Total Assets
32.5B
↓ 0.88%
Total Liabilities
18.4B
↑ 5.57%
FY23Y/Y Change
Total Assets
32.1B
↓ 4.18%
Total Liabilities
18.9B
↓ 0.34%
Q1 FY23Q/Q Change
Total Assets
32.8B
↑ 0.0%
Total Liabilities
17.5B
↓ 6.06%
Q2 FY23Q/Q Change
Total Assets
32.0B
↓ 3.85%
Total Liabilities
18.8B
↑ 6.09%
Q4 FY23Q/Q Change
Total Assets
32.1B
↓ 0.34%
Total Liabilities
18.9B
-
Q2 FY24Q/Q Change
Total Assets
31.7B
-
Total Liabilities
18.9B
-
FY18Y/Y Change
Operating Cash Flow
2.0B
↓ 4.81%
Investing Cash Flow
-1.7B
↓ 53.55%
Financing Cash Flow
-1.4B
↓ 2267.27%
FY19Y/Y Change
Operating Cash Flow
2.3B
↑ 14.1%
Investing Cash Flow
-670.1M
↓ 59.42%
Financing Cash Flow
-1.9B
↑ 39.68%
FY20Y/Y Change
Operating Cash Flow
3.4B
↑ 36.73%
Investing Cash Flow
-1.6B
↑ 118.24%
Financing Cash Flow
587.5M
↓ 129.01%
FY21Y/Y Change
Operating Cash Flow
1.8B
↓ 41.34%
Investing Cash Flow
-4.2B
↑ 179.03%
Financing Cash Flow
-2.7B
↓ 585.92%
FY22Y/Y Change
Operating Cash Flow
-183.1M
↓ 110.62%
Investing Cash Flow
-1.6B
↓ 59.5%
Financing Cash Flow
529.1M
↓ 121.3%
Q4 FY20Q/Q Change
Operating Cash Flow
3.3B
↑ 284.14%
Investing Cash Flow
-1.6B
↑ 131.69%
Financing Cash Flow
587.5M
↓ 35.69%
Q2 FY21Q/Q Change
Operating Cash Flow
914.8M
↓ 71.74%
Investing Cash Flow
-3.9B
↑ 143.69%
Financing Cash Flow
242.0M
↓ 58.39%
Q4 FY21Q/Q Change
Operating Cash Flow
5.7B
↑ 562.11%
Investing Cash Flow
-4.2B
↑ 14.5%
Financing Cash Flow
-2.7B
↓ 1267.66%
Q2 FY22Q/Q Change
Operating Cash Flow
-625.2M
↓ 111.74%
Investing Cash Flow
-927.7M
↓ 76.12%
Financing Cash Flow
369.2M
↓ 114.87%
Q4 FY22Q/Q Change
Operating Cash Flow
110.1M
↓ 117.6%
Investing Cash Flow
-1.6B
↑ 69.56%
Financing Cash Flow
529.1M
↑ 43.27%
Q2 FY23Q/Q Change
Operating Cash Flow
390.5M
↑ 246.15%
Investing Cash Flow
-389.4M
↓ 75.86%
Financing Cash Flow
-182.2M
↓ 133.6%

Technicals Summary

Sell

Neutral

Buy

Koninklijke Philips N.v is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Koninklijke Philips N.v
Koninklijke Philips N.v
5.15%
49.25%
41.68%
-35.27%
-30.87%
Stryker Corporation
Stryker Corporation
12.3%
0.36%
24.19%
28.8%
65.26%
Boston Scientific Corp.
Boston Scientific Corp.
10.6%
20.32%
51.42%
80.93%
95.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
9.4%
-28.78%
-12.2%
-45.23%
-7.73%
Abbott Laboratories
Abbott Laboratories
3.57%
-5.84%
13.1%
-11.32%
35.19%
Medtronic Plc
Medtronic Plc
10.85%
5.57%
12.46%
-33.2%
-16.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Koninklijke Philips N.v
Koninklijke Philips N.v
75.3
NA
0.35
1.67
-0.05
0.01
NA
12.72
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Koninklijke Philips N.v
Koninklijke Philips N.v
Hold
$27.9B
-30.87%
75.3
-2.32%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
65.26%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
95.5%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-7.73%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
35.19%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.71%
30.16
12.06%

Insights on Koninklijke Philips N.v

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 4.13B → 4.46B (in $), with an average increase of 7.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -999.0M → 451.0M (in $), with an average increase of 321.5% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 9.7%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 116.2%

Institutional Holdings

  • Mondrian Investment Partners Ltd

    0.88%

  • Fiduciary Management, Inc. of Milwaukee

    0.72%

  • FMR Inc

    0.65%

  • BlackRock Inc

    0.60%

  • Dimensional Fund Advisors, Inc.

    0.43%

  • Morgan Stanley - Brokerage Accounts

    0.34%

Corporate Announcements

  • Koninklijke Philips N.v Dividends September,2022

    In the quarter ending September,2022. Koninklijke Philips N.v has declared dividend of $0.91

    Read More

Company Information

Koninklijke Philips N.V., commonly shortened to Philips, is a Dutch multinational conglomerate corporation that was founded in Eindhoven in 1891. Since 1997, it has been mostly headquartered in Amsterdam, though the Benelux headquarters is still in Eindhoven.

Organization
Koninklijke Philips N.v
Employees
68701
CEO
Mr. Roy Jakobs
Industry
Electronic Technology

Discover More

FAQs